No influence of dialysis on mirtazapine - A case report

Pharmacopsychiatry

Volumn 41, Issue 6, 2008, Pages 259-260

  Schlotterbeck, P M ^a,c   Vehren, T ^a   Milenovic, S ^a   Hiemke, C ^b   Kircher, T ^a   Leube, D ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF HOHENHEIM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; MIRTAZAPINE;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; DIALYSATE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG METABOLISM; FEMALE; HEMODIALYSIS; HOSPITAL ADMISSION; HUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BIOTRANSFORMATION; DEPRESSIVE DISORDER; DIALYSIS SOLUTIONS; FEMALE; HUMANS; KIDNEY FAILURE; MIANSERIN; RENAL DIALYSIS;

EID: 58049125758     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1083822     Document Type: Article

References (3)

1. Klaassen C-D. Principles of toxicology and treatment of poisoning. In: Brunton L, Lazo J, Parker K, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: The McGraw-Hill Companies 2005; 1739-1753
2. Murtagh F-E, Addington-Hall J, Higginson I-J. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis 2007; 14: 82-99
3. Shams M, Hiemke C, Härtter S. Therapeutic drug monitoring of the antidepressant mirtazapine and its N-demethylated metabolite in human serum. Ther Drug Monit 2004; 26: 78-84